Bristol-Myers Squibb 's Eliquis and Opdivo are expected to have a place among the top 10 U.S. drugs in 2026 , generating some 7.8 billion and 6.1 billion U.S. dollars in revenues , respectively . This statistic displays a projection of the top 10 pharmaceutical products in the United States by revenue in 2026 .
